ceNOS gene therapy

ceNOS gene therapy is an adenoviral-based gene therapy platform developed through a licensing agreement between Crucell and BIOA&D. The therapy utilizes an adenoviral vector (such as AdCMVceNOS) to deliver the gene encoding human constitutive endothelial nitric oxide synthase (ceNOS/eNOS) into vascular tissues. By restoring or enhancing the production of nitric oxide (NO), the therapy aims to counteract endothelial dysfunction and impaired NO bioavailability. Primary indications investigated in preclinical research include pulmonary hypertension, where it reduces hypoxic pulmonary vasoconstriction, and the prevention of restenosis following balloon angioplasty, where it inhibits vascular smooth muscle cell proliferation and neointima formation. The platform has demonstrated efficacy in rat and porcine models of arterial injury and pulmonary vascular disease.

Other names

eNOS gene therapyendothelial nitric oxide synthase gene therapyconstitutive endothelial nitric oxide synthase gene therapyAd-eNOS